Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.96 |
| ▸ | HTR2C | P28335 | 4/20 | 0.96 |
| ▸ | HTR6 | P50406 | 4/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.96 |
| ▸ | HTR1D | P28221 | 3/20 | 0.96 |
| ▸ | MPO | P05164 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | HTR1B | P28222 | 2/20 | 0.96 |
| ▸ | HTR7 | P34969 | 2/20 | 0.96 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.96 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | CTSK | P43235 | 1/20 | 0.96 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.93 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | AHR | P35869 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptamine SCHEMBL8660762 | 0.98 | PMP22 (0.96) | HTR2AHTR2CHTR6CYP3A4HTR1D | |
| Tryptamine SCHEMBL29373222 | 0.98 | HTR2A (1.00) | HTR2AHTR2CHTR6CYP3A4HTR1D | |
| Tryptamine SCHEMBL26725 | 0.98 | HTR2A (1.00) | HTR2AHTR2CHTR6CYP3A4HTR1D | |
| Tryptamine SCHEMBL8714244 | 0.98 | HTR2A (1.00) | HTR2AHTR2CHTR6CYP3A4HTR1D | |
| Tryptamine SCHEMBL4936407 | 0.96 | HTR2A (0.96) | HTR2AHTR2CHTR6CYP3A4HTR1D | |
| Tryptamine SCHEMBL9472063 | 0.96 | HTR2A (0.96) | HTR2AHTR2CHTR6CYP3A4HTR1D | |
| Tryptamine SCHEMBL274183 | 0.96 | PMP22 (1.00) | HTR2AHTR2CHTR6CYP3A4HTR1D | |
| Tryptamine SCHEMBL22127053 | 0.96 | HTR2A (0.96) | HTR2AHTR2CHTR6CYP3A4HTR1D | |
| Tryptamine SCHEMBL10874156 | 0.96 | HTR2A (0.96) | HTR2AHTR2CHTR6CYP3A4HTR1D | |
| Tryptamine SCHEMBL29771300 | 0.96 | HTR2A (0.96) | HTR2AHTR2CHTR6CYP3A4HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615585-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2025-09-11 | — | — | US | claimed |
| WO-2025099725-A1 | CONJUGATES AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2025-05-15 | — | — | WO | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| US-20130329216-A1 | METHODS AND KITS FOR DETECTION OF DRUGS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-12-12 | — | — | US | claimed |
| EP-2649443-A2 | METHODS AND KITS FOR DETECTION OF DRUGS | Ramot at Tel-Aviv University Ltd (IL) | 2013-10-16 | — | — | EP | claimed |
| WO-2012077110-A2 | METHODS AND KITS FOR DETECTION OF DRUGS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-06-14 | — | — | WO | claimed |
| EP-2134395-A1 | DEVICE AND METHOD FOR DELIVERY OF A MEDICAMENT | Duke University (US) | 2009-12-23 | — | — | EP | claimed |
| EP-1670314-A4 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA INC (US) | 2009-02-25 | — | — | EP | claimed |
| WO-2008121610-A1 | DEVICE AND METHOD FOR DELIVERY OF A MEDICAMENT | DUKE UNIVERSITY (US) | 2008-10-09 | — | — | WO | claimed |
| US-20080241255-A1 | DEVICE AND METHOD FOR DELIVERY OF A MEDICAMENT | DUKE UNIVERSITY (US) | 2008-10-02 | — | — | US | claimed |
| EP-1670314-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | Sequella, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | SEQUELLA, INC. | 2005-05-26 | — | — | US | claimed |
| WO-2005034857-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA, INC. (US) | 2005-04-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | C5, DDC, SAT1 | HTR2A 4486/4885HTR2C 4685/4885HTR6 4245/4885 |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | VDR, OPRD1, HTR1A | HTR2A 11/4885HTR2C 14/4885HTR6 33/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR2A 14/4885HTR2C 42/4885HTR6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.